The ICER Effect: Payer Perspectives

The ICER Effect: Payer Perspectives

How and where are ICER drug assessments influencing payer decision-making?
Institute for Clinical and Economic Review (ICER) drug assessments are growing in importance and grabbing headlines in the overheated US drug market. But what does pharma need to know about how they resonate with payers? How do payers view ICER and its methodology? In what ways are payers using ICER assessments, and to what extent are they influencing pricing, coverage and formulary placement decision-making? Turn to this report for US payer insights into the value and relevance of ICER.

Companies

Amgen, Lilly, Regeneron, Sanofi, Pfizer, Merck & Co., Biogen, Gilead Sciences, Eisai, Shire, CVS, Blue Cross, Express Scripts, Amarin, Centres for Medicare and Medicaid, Patients Rising, Xcenda, Alliance for Aging Research, Caremark, Department of Veterans Affairs, National Institute for Health and Care Excellence, Novartis Gene Therapies, Pacific Research Institute, Pharmaceutical Research and Manufacturers of America, Value Our Health, Academy of Managed Care Pharmacy, ICON, Medicaid